All
Current Applications of Artificial Intelligence in Oncology
April 27th 2023As we better understand the use of artificial intelligence in oncology, experts can improve outcomes, develop approaches to solve problems, advance the development of treatments that are made available to patients with cancer, and more.
Ceralasertib Shows Clinical Activity With or Without Olaparib in Gynecologic Cancers
April 27th 2023Treatment with ceralasertib with and without olaparib showed promising signals of clinical activity in multiple rare gynecologic cancers, according to findings presented at the European Society for Medical Oncology Gynaecologic Cancers Congress 2023.
FDA Type C Meeting Shows Clinical Activity of Darovasertib/Crizotinib in MUM
April 25th 2023Promising results from a type C meeting with the FDA has led to a phase 2/3 trial of darovasertib and crizotinib being initiated in 2023 for patients with first-line HLA-A2 negative metastatic uveal melanoma.
HRD Mutations Propel New Approaches in Uterine Cancer
April 25th 2023Significant rates of homologous recombination deficiency somatic gene mutations were found in patients with uterine serous cancer, resulting in possible implications for future testing and treatment for the patient population, according to the results of a research study.
Durvalumab/Tremelimumab for HCC in Patients Undergoing Liver Transplant
April 24th 2023Promising efficacy has been seen with the use of immunotherapy for the management of patients with hepatocellular carcinoma, Now, durvalumab and tremelimumab combination therapy is being studied for this patient population listed for a liver transplant.
Phase 1 Study Evaluates Combinations of EPI-7386 for Prostate Cancers
April 24th 2023A phase 1 trial of EPI-7386 will evaluate the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of the agent in combination with apalutamide or abiraterone acetate plus prednisone.
Post–COVID-19 Infection Remains a Concern in Patients With Cancer
Many questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Adjuvant Nivolumab/Ipilimumab Not Recommended for Localized RCC With High-Risk Features
April 20th 2023The phase 3 CheckMate 914 study has missed its primary end point, and the lack of efficacy of nivolumab plus ipilimumab over placebo in the study has led investigators to refer oncologists back to the standard of care, pembrolizumab, as seen in KEYNOTE-564.
Orca-Q Elicits Compelling Data Among Patients Undergoing Haplo HSCT
April 20th 2023In an interview, Samer A. Srour, MD, MS, reviewed data from the dose-expansion phase of an ongoing phase 1 trial of Orca-Q in the haploidentical stem cell transplant setting for patients with high-risk hematologic malignancies.